SCHEMBL21725646

SCHEMBL21725646

CCC(C)N1CCC[C@H]1c1cccc(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.50
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
TSHR P16473 1/20 0.40
LMNA P02545 1/20 0.40
JAK2 O60674 2/20 0.39
NTRK1 P04629 2/20 0.39
INSR P06213 1/20 0.39
LYN P07948 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
ROS1 P08922 1/20 0.39
FGR P09769 1/20 0.39
KIT P10721 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
TIE1 P35590 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725645 0.86 RIPK1 (0.54) RIPK1MAOBMAOATSHRLMNA
SCHEMBL4100913 0.86 RIPK1 (0.54) RIPK1MAOBMAOATSHRLMNA
SCHEMBL22871227 0.83 CHRNB2 (0.53) RIPK1DRD2DRD3
SCHEMBL4106406 0.82 RIPK1 (0.50) RIPK1MAOBMAOATSHRLMNA
SCHEMBL18781020 0.82 RIPK1 (0.38) RIPK1DRD2DRD3MAOBMAOA
SCHEMBL23449302 0.80 CETP (0.45) DRD2DRD3PIK3C3
SCHEMBL27962870 0.80 RIPK1 (0.52) RIPK1MAOBMAOATSHRJAK2
SCHEMBL24757139 0.79 CHRNB2 (0.47) RIPK1DRD2DRD3
SCHEMBL19275745 0.77 RIPK1 (0.58) RIPK1MAOBMAOATSHRLMNA
SCHEMBL27745234 0.77 RIPK1 (0.49) RIPK1MAOBMAOATSHRJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885DRD2 371/4885DRD3 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.